FGTI-2734克服ERK介导的耐药并增强MRTX1133在KRAS G12D胰腺癌中的疗效
本研究探讨双法尼基转移酶和香叶基香叶基转移酶-1抑制剂FGTI-2734通过破坏野生型RAS膜定位,阻断MRTX1133诱导的ERK反馈再激活。在KRAS G12D胰腺癌细胞系和12例患者来源类器官中,联合用药显示协同抑制增殖和诱导凋亡,且与肿瘤分期、治疗状态或MRTX1133耐药无关。体内实验证实FGTI-2734增强MRTX1133抗肿瘤活性并抑制ERK再激活。
要点
- FGTI-2734阻断MRTX1133诱导的ERK反馈再激活
- 联合用药在KRAS G12D胰腺癌类器官中显示协同作用
- 体内实验证实联合治疗增强抗肿瘤活性并诱导显著肿瘤消退
核心结论
- FGTI-2734与MRTX1133联合可克服KRAS G12D胰腺癌对MRTX1133的适应性耐药。
研究设计与样本
- 研究使用KRAS G12D胰腺癌细胞系、12例患者来源类器官(包括原发和转移肿瘤,携带KRAS、TP53、CDKN2A、SMAD4、RTKs、PI3K/AKT、JAK/STAT、DNA修复/细胞周期和染色质修饰等多样基因改变)以及原位患者来源异种移植模型和细胞系异种移植模型。
主要发现
- FGTI-2734阻断MRTX1133诱导的ERK反馈再激活,并与MRTX1133协同抑制KRAS G12D胰腺癌细胞增殖和诱导凋亡。
- 在12例患者来源类器官中,MRTX1133/FGTI-2734联合产生强协同作用,与肿瘤分期、治疗状态或MRTX1133耐药无关。
- 体内实验中,FGTI-2734增强MRTX1133抗肿瘤活性,在放疗和化疗后复发的KRAS G12D胰腺癌患者来源原位异种移植模型及人胰腺肿瘤细胞系异种移植模型中驱动显著肿瘤消退。
- 小鼠经FGTI-2734治疗可抑制KRAS G12D胰腺癌异种移植中MRTX1133诱导的ERK再激活。
临床怎么用
- 对于KRAS G12D胰腺癌,联合FGTI-2734可能克服MRTX1133耐药,为包括难治性患者提供潜在治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The KRAS G12D inhibitor MRTX1133 represents a major advance in targeting oncogenic KRAS, but adaptive resistance driven by ERK reactivation, dependent on wild-type (WT) RAS membrane localization, limits its efficacy. RESULTS: Here, we identify a rational strategy to overcome this resistance mechanism using FGTI-2734, a dual farnesyltransferase (FT) and geranylgeranyltransferase-1 (GGT-1) inhibitor that disrupts WT RAS membrane localization. FGTI-2734 blocks MRTX1133-induced ERK feedback reactivation and synergizes with MRTX1133 to inhibit proliferation and induce apoptosis in KRAS G12D pancreatic cancer cell lines. Across organoids derived from 12 patients with KRAS G12D pancreatic cancer, including those with primary and metastatic tumors with diverse genetic alterations (KRAS, TP53, CDKN2A, SMAD4, RTKs, PI3K/AKT, JAK/STAT, DNA repair/cell cycle, and chromatin modifiers), the MRTX1133/FGTI-2734 combination produced robust synergy regardless of tumor stage, treatment status, or MRTX1133 resistance. In vivo, FGTI-2734 enhanced MRTX1133 anti-tumor activity, driving significant tumor regression in orthotopic patient-derived xenografts from a KRAS G12D pancreatic cancer patient who relapsed after radiation and chemotherapy, as well as KRAS G12D human pancreatic tumor cell xenografts. Notably, treatment of mice with FGTI-2734 inhibited MRTX1133-induced ERK reactivation in KRAS G12D pancreatic cancer xenografts. CONCLUSION: These findings establish a combination strategy that overcomes a significant mechanism of resistance to MRTX1133 and offer a potential treatment option for pancreatic cancers, including those refractory to current therapies.
引用
- Ghosh D, Kazi A, Vasiyani HKK, et al. FGTI-2734 prevents ERK-mediated resistance and enhances MRTX1133 efficacy in KRAS G12D pancreatic cancer. Eur J Cancer. 2026. PMID: 41722442. doi:10.1016/j.ejca.2026.116255
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。